Skip to main content

Share story

Products Policy

Claims open in Apple's proposed $250 million Siri-delay settlement

Claims open in Apple's proposed $250 million Siri-delay settlement Image: Primary
U.S. consumers can now file claims in Apple's proposed $250 million settlement of litigation over delays to a more personalized Siri. Eligibility covers people who bought an Apple Intelligence-capable iPhone in the United States from June 10, 2024, through March 29, 2025, and claims are due December 21, 2026. The expected payment is $25 per eligible device, subject to participation, with a maximum of $95. Apple admits no wrongdoing. A final approval hearing is scheduled for September 29, 2027, and payments would begin at least 60 days later, so opening the claims process does not make the settlement or payouts final.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from 9to5Mac and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Security Infrastructure
Security Infrastructure

Ransomware attack halts trading on Nepal Stock Exchange

The Nepal Stock Exchange suspended all Monday trading after ransomware hit infrastructure hosting the trading systems of 72 brokerages. Data Hub detected the attack early that morning and kept affected systems offline while invest...

Security
Security

Gyazo breach exposed metadata for 490 million images

A breach at screenshot-sharing service Gyazo exposed nearly 24 million customer records and an additional 490 million image-metadata records, Infosecurity Magazine reported. Attackers exploited an upload-server vulnerability, gain...

AI Products
AI Products

Tech groups use residual-value guarantees to lower AI financing costs

Large technology companies are increasingly using residual-value guarantees to finance AI equipment off their balance sheets, the Financial Times reports. The guarantees apply the companies' credit strength to the hardware's futur...

Capital Products
Capital Products

Novadip raises €10.4 million to complete pivotal bone-graft trial

Belgian regenerative-medicine company Novadip Biosciences has closed a €10.4 million convertible financing led by New Science Ventures. The funding will support completion of an ongoing Phase 3 trial in the United States and Europ...